mash novo nordisk - Search News

News

Wegovy News Pushes Novo Nordisk Stock

Barron's on MSN · 1h

Wegovy News Pushes Novo Nordisk Stock Higher

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

CNBC on MSN · 9h

Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.

Investopedia on MSN · 5h

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious disease of the liver.

1h

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

MedPage Today7m

Semaglutide Gets FDA Greenlight for MASH

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

3hon MSN

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

4h

Novo Nordisk stock soar 5% today: here’s why analysts are bullish

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results